Imprivata Webinar to Outline Regulatory and Technology Requirements for Electronic Prescribing of Controlled Substances

Presented by HISTalk, Webinar will Highlight the Benefits of EPCS, including Improving Prescribing Workflow Efficiency, Minimizing Medication Errors and Reducing Drug Diversion and Fraud

LEXINGTON, Mass.--()--Imprivata® (NYSE: IMPR), a leading provider of authentication, access management and secure communications solutions for the healthcare industry, today announced that the company will host a webinar titled “Electronic Prescribing of Controlled Substance Is Here, What Should You Do?” on Tuesday, October 21, 2014 at 1:00 p.m. EDT. Presented by HIStalk, the webinar will provide an overview of the Drug Enforcement Administration (DEA) requirements for electronic prescribing of controlled substances (EPCS), the benefits and the scope of work involved in implementing EPCS.

In 2010, the DEA finalized an interim final rule allowing EPCS, which promises to deliver significant benefits, including:

  • Reduced risk of altered, stolen or fraudulent prescriptions, helping to combat drug diversion and prescription medication abuse
  • Improved patient safety and satisfaction
  • Increased e-Prescribing utilization to help meet Meaningful Use requirements
  • Improved prescriber satisfaction
  • Reduced prescription errors and inaccuracies

To enable EPCS, organizations must meet the DEA requirements, including identity-proofing prescribers, two-factor authentication for prescription signing and maintaining an audit trail of the EPCS process. The “Electronic Prescribing of Controlled Substance Is Here, What Should You Do?” webinar will provide more detail on these and other requirements, and outline specific processes organizations can implement to launch a successful EPCS initiative. Speakers include:

  • William Winsley, MS, RPh, former executive director of the Ohio State Board of Pharmacy
  • Sean P. Kelly, M.D., an emergency physician at Beth Israel Deaconess Medical Center in Boston and Chief Medical Officer at Imprivata
  • David Ting, founder and CTO at Imprivata

To register for the “Electronic Prescribing of Controlled Substance Is Here, What Should You Do?” webinar, please click here.

About Imprivata

Imprivata (NYSE: IMPR) is a leading provider of authentication and access management solutions for the healthcare industry. Imprivata’s single sign-on, authentication management and secure communications solutions enable fast, secure and more efficient access to healthcare information technology systems to address multiple security challenges and improve provider productivity for better focus on patient care. For more information, please visit www.imprivata.com.

Contacts

PR Contact:
Imprivata
Dan Borgasano, 781-430-2812
dborgasano@imprivata.com
or
IR Contact:
Westwicke Partners
Bob East / Asher Dewhurst, 443-213-0503
bob.east@westwicke.com
imprivata@westwicke.com

Release Summary

Imprivata® (NYSE: IMPR) today announced that the company will host a webinar titled “Electronic Prescribing of Controlled Substance Is Here, What Should You Do?” on Tuesday, October 21, 2014 at 1 p.m.

Contacts

PR Contact:
Imprivata
Dan Borgasano, 781-430-2812
dborgasano@imprivata.com
or
IR Contact:
Westwicke Partners
Bob East / Asher Dewhurst, 443-213-0503
bob.east@westwicke.com
imprivata@westwicke.com